• Flora Growth recently announced it had signed an LOI to provide a Panama-based international importer and distributor with cannabinoid-containing food and beverages
• The announcement followed on the heels of regulatory changes passed by Panama’s National Legislative Assembly, which legalized the use of medical cannabis and its therapeutic properties
• In July, Flora Growth signed an LOI with an international distributor to supply its dried flower and derivatives, an immediate result of the legalization of the export of dried cannabis flower by Colombia’s government

As a wave of cannabis-focused regulatory changes sweeps across Latin America and the world at large, Flora Growth (NASDAQ: FLGC), an internationally focused cannabis brand builder leveraging natural, cost-effective cultivation practices to supply cannabis flower and derivatives to its diverse business divisions, is proving quick to take advantage of these opportunities. Following the legalization by Colombia’s government for the export of dried cannabis flower in July this year, for example, Flora immediately reacted, demonstrating an unmatched strategic readiness to make moves right away. The company signed a letter of intent (“LOI”) with Kiricann, a South Africa-based international distributor with distribution agreements in the EU, to supply its dried flower and derivatives (https://ibn.fm/2WsBq). Additionally, the company signed a non-binding LOI with Evergreen Pharmacare, a licensed Australia-based importer and distributor of medical cannabis products, to supply its premium dried flower and derivatives. According to a recent Benzinga article, the Colombian law positioned the company for continued expansion into global markets. Flora Growth, which boasts robust infrastructure, access to skilled agricultural labor, and a strong distribution network, is ideally poised for exports of its cannabis products to do very well worldwide (https://ibn.fm/oGUIN). The company’s low production cost of only $0.06 per gram of cannabis, which is approximately 97% less than the reported costs of Canadian companies Aphria ($1.85 per gram), Sundial ($1.86 per gram), and Tilray (NASDAQ: TLRY) ($2.36 per gram) (https://ibn.fm/Dewwf), equally give it a substantial competitive edge. In a move that appears to capitalize on these favorable conditions as well as the regulatory changes passed by Panama’s National Legislative Assembly on August 30, Flora Growth announced September 16 that it had signed an LOI with Panama-based Robust Farms Inc., an international importer and distributor. Under the terms contained in the letter, Flora will provide Robust Farms with cannabinoid-containing food and beverages through its Kasa Wholefoods division, a Colombian manufacturer of food and beverages. The Panamanian changes, contained in Bill 153, legalized the use of medical cannabis and its therapeutic properties and further created a regulatory framework to monitor and control access. Following the changes, authorized patients will have the right to access medical cannabis products through licensed pharmacies that will be responsible for distribution. “It’s expected that Panama will become the first country in Central America to regulate the use of medical cannabis, however, the new regulations must be approved by President Laurentino Cortizo,” the article notes. Flora Growth President and CEO Luis Merchan lauded Panamanian legislators and advocacy groups for their efforts to push forward the initiative to control and regulate medical cannabis. “Ultimately,” he continued, “it will help provide options for patients who are looking to improve their quality of life by utilizing emerging cannabinoid therapeutic treatment. We look forward to working with local partners to provide our cannabis products to the citizens of Panama.” As Flora Growth continues its global expansion, it is focused on creating a balance between international collaborations and serving local communities. The company intends to prioritize the protection of the earth and its resources and, therefore, first considers the global impacts of its actions before acting on a local level. This approach helps Flora enact positive connections to the communities it inhabits and stand out, particularly in Colombia. Flora Growth operates one of the largest outdoor cultivation facilities in the world with the aim of marketing a higher-quality premium product at below-market prices. Flora Growth offers low-cost cannabis cultivation through its 10.8 million square feet (247 acres) of licensed cultivation land in Colombia, an expansive product and brand portfolio, as well as a strategic global distribution platform. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

Date: October 29, 2021 Online Virtual Event Entrepreneurs, traders, investors, developers, fintech professionals, and industry enthusiasts are invited to the 3rd Annual Crypto Fest, scheduled for October 29, 2021. The first Crypto Fest, held back in 2019 in Cape Town, South Africa, was a first in the industry. The second one was held virtually in 2020, paving the way for the third edition that promises to be bigger and better. Presented by Bitcoin Events, Crypto Fest 2021 will have over 2,500 attendees, mainly comprising of technical decision-makers, payment specialists, global policymakers, marketing specialists, industry innovators, forex, and cryptocurrency traders, among others. Over 30 global innovators and thought leaders in the cryptocurrency and blockchain industry will present at the event, offering their informed opinions on critical issues and topics within the space. Bitcoin Events is Africa’s leading blockchain and cryptocurrency event organizer, a position it has held since 2015. It is the first company to host world-class bitcoin and blockchain conferences in the African market, with a combined attendance of over 12,000 from over 165 countries worldwide. Bitcoin Events takes the learnings from previous events to this third edition of the Crypto Fest, its most ambitious one yet. Attendees can expect networking opportunities with some of the industry’s most progressive professionals in finance, trading, mining, insurance, auditing, legal, software infrastructure, and more. They can also explore exciting collaborations and create new strategic partnerships, ultimately discovering the latest blockchain and cryptocurrency solutions, products, platforms, and services at the available exhibition booths. Speakers at the event will be drawn from various backgrounds to debate and contest controversial topics, tackling them from a unique standpoint. Attendees will also stand a chance to win prizes and giveaways from the event’s sponsors and partners. Sponsors of the event include the Amber Group, FTX, Svalbard money and CCW. This event will also feature trading and investment workshops where expert crypto traders and investors will teach attendees about the different tools, techniques, and platforms available for effective trading and investment. There will also be a Q&A session where experts and panelists will answer attendees’ questions. The 2021 Crypto Fest promises to be engaging, informative, and ground-breaking. It will tackle everything from controversial topics to the intricacies of Non-Fungible Tokens (“NFTs”) and Decentralized Finance (“DeFi”). Attendees will better understand regulations surrounding these two topics and the expectations that bitcoin and alternative currencies are slowly gaining traction worldwide. The event promises value and an opportunity for attendees to thrive in their respective industries.

• To learn more about the event, please visit our page (https://ibn.fm/iRUha)
• If interested in attending this virtual event, visit (https://ibn.fm/RjAIb)
• Should you wish to become a speaker at the event, please register using this link (https://ibn.fm/zqSlw)
• To sponsor the event, please visit this page (https://ibn.fm/hf8w2)
• To exhibit at the event, please register here (https://ibn.fm/uaNt8)

• Pharmacy services developer Avricore Health recently completed the initial phase of rolling out its HealthTab(TM) platform
• HealthTab(TM) partners with other health technology platforms to collect data from blood or other molecular samples to test them for illnesses ranging from COVID and flu to heart disease and diabetes
• Avricore’s platform is designed to not only provide medical condition information to patients, but to share it seamlessly with medical providers and researchers
• The company’s initial rollout took place through pharmacies in Ontario, Canada, but Avricore intends to continue expanding throughout Canada, into the United States and eventually into Europe

Health diagnostics technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has completed the initial rollout of its point of care platform for providing patients with lab-quality results regarding COVID and other illnesses, and the company was featured just recently in a Bell2Bell podcast discussing its history, its next goals and the plans it has for development farther down the road. “I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future,” Avricore CEO Hector Bremner told Bell2Bell’s Stuart Smith (https://ibn.fm/PxlqO). “We’re really passionate about leading this charge. … We’ve now got a company that is in great shape and fully funded. And we’re growing, and we’ve got really a lot of blue sky ahead of us.” Avricore’s flagship HealthTab(TM) platform partners currently with Abbott Rapid Diagnostics’ Afinion 2(TM) and ID Now(TM) analyzers, as well as Abaxis Global Diagnostics’ Piccolo Xpress to conduct blood or molecular testing at a neighborhood pharmacy and then shares the data from the tests not only with the patient, but also with medical professionals and researchers without compromising health privacy. “Really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data and that can be used for study and research purposes, which is a very, very high demand out there in the sector,” Bremner said. For the patient’s part, once the simple sample is collected testing takes about 15 minutes to deliver the results. The initial rollout has been accomplished by partnering with the Shoppers Drug Mart pharmacy network in Ontario, Canada, but the company anticipates continuing to expand through Shoppers Drug Mart’s almost 1,800 pharmacies across Canada, adding other pharmacies, and then entering the United States and the United Kingdom as well. “The nice thing is all this technology that we use, everything that we’re doing down there (in the United States), is already approved so we are not at a sort of regulatory or approval risk at any level expanding internationally,” he said. “We’re also really excited about opportunities in the UK and EU, which, I think people just don’t understand how big a market that really is — it’s still bigger than China and it is a place where I think we can do business reliably. Between the U.S., UK and Canada, there’s about 110,000 pharmacies.” Bremner said Avricore Health is also generating interest among Latin American and Caribbean countries for applications of its network in travel-related infectious disease diagnostics. The company’s cloud-based technology provides a network for high-quality analysis not only for illnesses such as COVID and influenza, but heart disease and diabetes as well, facilitating data-based follow-ups with medical providers. The global point-of-care diagnostics market was measured at nearly $34.5 billion in revenue last year by Fortune Business Insights, and it is expected to continue growing at a compound annual growth rate (“CAGR”) of 9.4 percent through 2028 (https://ibn.fm/WFy4E). For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Pharmacy services developer Avricore Health recently completed the initial phase of rolling out its HealthTab(TM) platform
• HealthTab(TM) partners with other health technology platforms to collect data from blood or other molecular samples to test them for illnesses ranging from COVID and flu to heart disease and diabetes
• Avricore’s platform is designed to not only provide medical condition information to patients, but to share it seamlessly with medical providers and researchers
• The company’s initial rollout took place through pharmacies in Ontario, Canada, but Avricore intends to continue expanding throughout Canada, into the United States and eventually into Europe

Health diagnostics technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has completed the initial rollout of its point of care platform for providing patients with lab-quality results regarding COVID and other illnesses, and the company was featured just recently in a Bell2Bell podcast discussing its history, its next goals and the plans it has for development farther down the road. “I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future,” Avricore CEO Hector Bremner told Bell2Bell’s Stuart Smith (https://ibn.fm/PxlqO). “We’re really passionate about leading this charge. … We’ve now got a company that is in great shape and fully funded. And we’re growing, and we’ve got really a lot of blue sky ahead of us.” Avricore’s flagship HealthTab(TM) platform partners currently with Abbott Rapid Diagnostics’ Afinion 2(TM) and ID Now(TM) analyzers, as well as Abaxis Global Diagnostics’ Piccolo Xpress to conduct blood or molecular testing at a neighborhood pharmacy and then shares the data from the tests not only with the patient, but also with medical professionals and researchers without compromising health privacy. “Really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data and that can be used for study and research purposes, which is a very, very high demand out there in the sector,” Bremner said. For the patient’s part, once the simple sample is collected testing takes about 15 minutes to deliver the results. The initial rollout has been accomplished by partnering with the Shoppers Drug Mart pharmacy network in Ontario, Canada, but the company anticipates continuing to expand through Shoppers Drug Mart’s almost 1,800 pharmacies across Canada, adding other pharmacies, and then entering the United States and the United Kingdom as well. “The nice thing is all this technology that we use, everything that we’re doing down there (in the United States), is already approved so we are not at a sort of regulatory or approval risk at any level expanding internationally,” he said. “We’re also really excited about opportunities in the UK and EU, which, I think people just don’t understand how big a market that really is — it’s still bigger than China and it is a place where I think we can do business reliably. Between the U.S., UK and Canada, there’s about 110,000 pharmacies.” Bremner said Avricore Health is also generating interest among Latin American and Caribbean countries for applications of its network in travel-related infectious disease diagnostics. The company’s cloud-based technology provides a network for high-quality analysis not only for illnesses such as COVID and influenza, but heart disease and diabetes as well, facilitating data-based follow-ups with medical providers. The global point-of-care diagnostics market was measured at nearly $34.5 billion in revenue last year by Fortune Business Insights, and it is expected to continue growing at a compound annual growth rate (“CAGR”) of 9.4 percent through 2028 (https://ibn.fm/WFy4E). For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Tryp Therapeutics recently launched a new website with updated resources to be featured on the site
• Over the next few weeks, the company will share key resources that will be the standout features of the new website
• Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring relief to millions of people worldwide who are dealing with conditions such as fibromyalgia, CRPS, and Phantom Limb Pain but lack proper treatment for their conditions. In a move that demonstrates its commitment to taking its operations further and having even a broader market reach, Tryp recently updated its website in an act to better represent the company’s current stage of development. Additionally, it plans to distribute critical resources that will be featured on its updated site, and which will act as a tool for the investment community. Some of these resources will include an Investor Pack that will cover Tryp’s pitch deck, a factsheet, and a Frequently Asked Questions (“FAQ”) section. There will also be a dedicated FAQ for patients, coupled with a series of short QA videos from the management team. The updated website will also feature market opportunity info, along with QA with two key individuals. One will be Dr. Jennifer Miller, the Principal Investigator for a clinical trial to treat symptoms associated with eating disorders (https://ibn.fm/DQChR), and the other will be Kevin Boehnke, the Principal Investigator for Phase 2a clinical trial on the treatment of fibromyalgia (https://ibn.fm/Z8RON). Tryp believes that making these critical resources assessable on the website will present more diligence opportunities to patients suffering from their targeted indications and existing investors. It also believes that by doing so, it will bring in more individuals who will share in its course, allowing them to be part of a movement dedicated to improving millions of lives around the world (https://ibn.fm/rVAHw). Over the next few weeks, the company provide updates regarding essential resources that will be the standout features of the new website. This is happening in tandem with ushering a new era for psilocybin, with Tryp’s commitment to revolutionizing what psilocybin-based treatments can do with leading-edge therapies for chronic pain and other indications. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• FingerMotion’s R&D expenditure has been gradually increasing quarter over quarter and year on year, representing its focus on the development of innovative mobile payment and communication products for over 1/2 million users in China
• The company’s Big Data Insights division, Sapientus, which has accounted for most of the R&D expenditure so far, has been several years in the making
• FingerMotion is looking to establish a collaborative lab with partners to run as a joint research and analytics hub
• In March 2020, FNGR set aside resources dedicated to the R&D of an RCS platform

A look at several of the recent forms 10-K (annual report) and 10-Q (quarterly report) that evolving technology company FingerMotion (OTCQX: FNGR) has filed with the SEC shows interesting trends. These trends, which point to an ever-increasing focus on research and development (“R&D”), further bolster the company’s commitment to developing “must-have” applications for both consumers and businesses. In the three months ended November 30, 2020 (Q3 2021), the company’s R&D expenditure was up 29% to $124,723 from $96,627 reported in Q3 2020 (https://ibn.fm/tlNI4). The increase contributed to a year-end R&D expenditure of $552,343 for the fiscal year ended February 28, 2021 (FY 2021), representing a year-over-year increase of 42% (from $390,288 in FY 2020). Similarly, the company’s R&D spending increased to $135,429 in the three months ended May 31, 2021 (Q1 2022), up from $103,610 expended in Q1 2021 (https://ibn.fm/gYZff). According to the financial statements, FNGR’s youngest operational division, Sapientus, launched mid last year, accounted for most of the expenditure. Through Sapientus, FingerMotion delivers big data-enabled insurance solutions (behavioral insights) that augment existing service offerings and increase insurers’ ability to calculate risks and develop more innovative products. The division generated $33,077 in revenue in Q4 2021 and $98,715 in Q1 2022. This quarter-over-quarter increase marked significant progress in Sapientus’ success, which has been several years in the making. “In the past few years, we’ve had our inhouse team of actuaries and data scientists, who really know the ins and outs of the insurance industry, and what they’ve been doing is they’ve been deciphering information from all these different sources and putting them in the risk metrics that could provide those fresh insights and intelligence for the insurance field,” explains FingerMotion CEO Martin Shen in the company’s August corporate update (https://ibn.fm/fYdqr). FingerMotion believes that by integrating its Sapientus data blocks with external data sources such as industry reports and compiled data published by researchers, its R&D departments can develop innovative insurtech and fintech products for its customers. The company is also looking to leverage key partnerships. “One of our exciting moves is that we are looking to establish a collaborative lab with our partners. This lab will run as a joint research and analytics hub to further develop the advanced behavioral modeling algorithms that we already have, improve the insights that we are developing, and support some of those innovative products for insurance customers and then help them assess that overall risk,” Shen continued. FNGR’s focus on R&D as an instrument for innovation is not just constrained to its Big Data insights operations. Its form 10-K for the most recent financial year, for instance, noted that in March 2020, the company’s management allocated resources toward the R&D of a Rich Communications Services (“RCS”) platform (https://ibn.fm/brOOB). An emerging and formidable technology, RCS is revolutionizing text-based messaging by eliminating the constraints associated with short text messaging. It offers expanded capabilities such as file sharing, group chat, video calling, and more from the native messaging service without using a third-party app. The burgeoning RCS market is projected to grow at a 17.6% CAGR from 2020 to 2025, topping out at a value of $11.7 billion (https://ibn.fm/JstRr). FingerMotion is looking to tap into this growth through the expected launch of the RCS division, having already commenced R&D efforts. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• The company believes that the study findings support its patented DehydraTECH(TM) system as being the world’s fastest-acting nicotine through oral absorption and a safer nicotine alternative for the 1.1 billion smokers of the world
• Plans for a human trial are in the design process, and Lexaria intends to use existing capital to execute the study
• The global nicotine pouch market is expected to grow to a total revenue of $21.84 billion by the end of 2027, a CAGR growth of 30.7% over the forecast period

A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) has announced the results of its recent NIC-A21-1 study on oral nicotine absorption, indicating that DehydraTECH(TM)-nicotine delivered by an oral pouch product format required two to four minutes to deliver the desired nicotine levels in blood plasma versus the 45 minutes with concentration-matched controls. Lexaria believes that the study’s findings support the world’s fastest-acting nicotine oral mucosal absorption market and offer a safer alternative for 1.1 billion smokers as a means of cessation (https://ibn.fm/gWi5h). The key pharmacokinetic findings of the study support a statistically significant improvement in the delivery and peak levels of absorption. As a result of the performance of this study in animals, Lexaria’s next step is to progress to a larger investigation using human volunteers. The company will compare the DehydraTECH-nicotine pouches performance (using DehydraTECH-2.0) against existing brands like Zyn (Swedish Match) and ON! (Altria). The human study is currently in the design phase, and Lexaria intends to fund it with existing capital. Lexaria is optimistic that the upcoming human trials will produce even more positive findings.  Lexaria’s own research has demonstrated nicotine in the bloodstream in as little as 1.5-4.0 minutes after oral ingestion.  These results align with the current dog study, in which DehydraTECH-nicotine required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. “We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral pouch formulations in this study. Our technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction,” Lexaria CEO Chris Bunka said. “Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete.” Smoking is one of the world’s most preventable health hazards. According to the World Health Organization (“WHO”), tobacco kills more than 8 million users each year – 7 million of which are direct tobacco users, whereas approximately 1.2 are those exposed to second-hand smoke. Without cessation support, only 4% of those who attempt to quit smoking are successful (https://ibn.fm/msDQn). The performance of DehydraTECH in this study indicates that the technology is ideal for the oral nicotine pouch market, one of the fastest growing nicotine sectors in the world, and could help revolutionize the nicotine industry as a whole. The global nicotine pouch market reached a value of $2.33 billion in 2020 and is expected to grow at a high CAGR (30.7%) during the forecast period of 2021-2027, to reach approximately $21.84 billion in revenue by the end of 2027 (https://ibn.fm/XXgFM). The NIC-A21-1 study was performed in a leading, independent testing laboratory using 40 anesthetized male beagle dogs, divided into four groups of ten. All of the beagles used in the study were attended to with the highest levels of care, tolerated the DehydraTECH pouches well, and were returned to full health at the conclusion of the study. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Cybin names Dr. Amir Inamdar as chief medical officer for European operations
• The company appoints Dr. Geoff Varty as head of research and development
• Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics

As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made key additions and changes (https://ibn.fm/0GBMQ). Most recently the company has appointed two new executives and announced internal promotions to continue strengthening its leadership team. Cybin has named Dr. Amir Inamdar as chief medical officer for European operations and Dr. Geoff Varty as head of research and development for the company. In addition, the company announced the promotion of Lori Challenger to chief compliance, ethics and administrative officer and Robert Mino to general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug development experience, Dr. Amir Inamdar has garnered invaluable experience in progressing several drugs from preclinical development to early-phase clinical trials; he also has key experience in designing and delivering proof-of-concept studies as well as leading teams through marketing authorization applications. Inamdar’s background stretches across diverse psychiatric indications, including schizophrenia, depression, bipolar disorder, treatment-resistant mental illnesses and substance-use disorders. He has led multidisciplinary teams, providing strategic direction and clinical and scientific leadership. Inamdar has also received numerous awards for his research and development work in clinical drug development. Inamdar has worked at GlaxoSmithKline, Takeda Pharmaceutical Company Limited and AstraZeneca. In his roles at these organizations, he developed a network of excellence in psychiatry and provided medical leadership to enable the development of candidate drugs from selection through to proof-of-concept trials across a variety of central nervous system indications. He was also key in successfully obtaining marketing authorization for an antipsychotic in Europe, progressing small molecules from candidate selection to first in-human studies, and leading clinical teams in treatment of resistant depression, narcolepsy and anxiety. Varty too brings an impressive history of work expertise. A highly experienced neuroscientist and drug discoverer, Varty also has a track record of progressing novel molecular entities into clinical trials and to the patient. With a bachelor’s degree in pharmacology and a PhD in neuropsychopharmacology, Varty has focused his research on the development of behavioral models for psychosis and cognition, along with the preclinical testing of novel compounds. He has spent his two-decade career in the pharmaceutical industry, working in R&D and scientific leadership and managerial roles at Schering Plough, Sanofi and Merck. While at these companies, Varty led in-vivo research in several central nervous system–related areas such as pain, anxiety, depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. He has also gained invaluable experience collaborating with cross-functional teams working together toward focused objectives. He has published more than 130 journal articles and abstracts. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• FinTech has become ubiquitous within the modern financial industry, with applications across the banking, e-commerce, and cryptocurrency sectors
• The emergence of fintech has led to the emergence of a variety of new services, ranging from Buy Now, Pay Later companies to digital, online-only banks
• Moon Equity Holdings, an investment company focused on acquisitions within the fintech, crypto, precious metals, and real estate sectors, has sought to capitalize on the growth within the digital currency sector through the creation of a cryptocurrency trading service

In August 2021, Square Inc (NYSE: SQ), the payment firm of Twitter co-founder Jack Dorsey, announced the acquisition of Australian ‘’Buy Now, Pay Later” (“BNPL”) firm, AfterPay (AX: APT) (OTC: AFTPF) in a mammoth $29 billion deal (https://ibn.fm/rZdYH). Paypal shortly followed this purchase announcing the takeover of Japanese BNPL firm Paidy in a $2.7 billion contract (https://ibn.fm/rXKZr). The emergence of the BNPL sector and their sizeable acquisition prices provide just one example of the increased ubiquity of fintech within the global finance industry today – a sector which Moon Equity Holdings (OTC: MONI), an investment company concentrating on acquisitions in real estate, precious metals, and cryptocurrency, is looking to harness. Fintech technologies have become an increasingly disruptive force within today’s global financial sector (https://ibn.fm/6ne8J); however, nowhere are they more prevalent than within the traditional banking industry. For example, the United Kingdom’s commercial banking sector has long been dominated by a handful of traditional banks; sector leader, Barclays Bank, was initially founded in 1690 and employs upwards of 83 thousand people today. However, over the past decade, the United Kingdom’s financial regulator has opted to introduce new regulations that have served to open the sector to new entrants. One of the United Kingdom’s fastest-growing financial institutions today is Monzo Bank, a digital bank founded as recently as 2015, which boasts next to no physical presence and employs less than 2 thousand people overall (https://ibn.fm/aynlB). Fintech has been instrumental in creating digital banks, with financial institutions increasingly shifting away from operating physical channels of interaction with customers and towards digital and mobile services instead. A similar situation has been witnessed within the e-commerce sphere, with the online shopping sector accounting for 19.6% of total US retail sales in 2020, a sizeable increase from 2018’s 14.3%. Again, fintech solutions have permitted online sellers to flourish in recent years, largely thanks to an expanded suite of services. These services provide merchants with easy access to capital to stabilize cash flow, enable customers to partake in various consumer point-of-sale financing solutions, and display pertinent and personalized product recommendations to online visitors. Cryptocurrencies and blockchain technology have rapidly emerged as the latest frontier within the fintech sector, with online financial tools solutions enabling users to quickly and efficiently mine and trade digital coins. Moon Equity Holdings, a pioneer within the global fintech sector, has sought to capitalize on the burgeoning interest within the industry, working on a crypto component currently under development, alongside two proprietary applications designed to revolutionize how people gift and purchase cryptocurrency. Through its venture into the digital currency space, Moon Equity Holdings expects to enhance customer experience and create a loyal following, generating repeat business. For more information, visit the company’s website at www.MoonEquityHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to MONI are available in the company’s newsroom at https://ibn.fm/MONI

• PlantX aims to make the plant-based lifestyle more accessible through education and collaboration
• The company has partnered with tennis icon Venus Williams, who was featured in a recent video podcast episode
• Venus recounted how a plant-based diet helped her get back into professional tennis after being diagnosed with an autoimmune disease in 2011; she made the 2012 US Olympics team
• Along with vodcast episodes, PlantX regularly posts blog articles on its website aimed at guiding people on the plant-based journey

Every Monday at 4:00 PM PST (7:00 PM EST), a video podcast episode goes live on PlantX Life’s (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) YouTube channel (https://ibn.fm/U1HkO). Part of an ongoing series also available via the company’s website, the vodcast episodes, which target the plant-based community, feed into the company’s education-oriented approach. Alongside the vodcast series are blog posts, weekly recipe videos (posted on YouTube), and collaborations with influential public figures following a plant-based lifestyle. Through these resources, PlantX, a one-stop shop for everything plant-based, wholesomely caters to the needs of the plant-based community. “We want people to come, learn, educate themselves on what a plant-based lifestyle is all about,” emphasizes PlantX Founder and host of the vodcast series Sean Dollinger in several of the vodcast episode’s introductions. In explaining the purpose behind the vodcast, Sean notes that the episodes aim at sharing the value of plant-based living with investors, shareholders, and, generally, all viewers. In season 2, episode 5, published on September 21, for example, Sean hosted marquee tennis player Venus Williams who narrates how she overcame Sjogren’s syndrome, an autoimmune disorder, with a plant-based diet (https://ibn.fm/Fdb4O). “I made the shift [to a plant-based diet] because I became so ill that I could no longer play professional sport… It literally came to a halt about ten years ago in the summer of 2011 to the point where I just started withdrawing from tournaments,” explains Venus. According to Venus, the disease caused debilitating fatigue, joint pains, and other symptoms, which impeded her ability to play tennis and negatively impacted her quality of life. Venus, who believed that the environment played a role in her situation, wanted to control the disease without using “tons of medication,” which are often very harsh. Based on a suggestion from her younger sister, Serena Williams, Venus began her plant-based journey, which proved beneficial. Not only was she able to make the 2012 Olympics team, but she also described experiencing glowing skin and a revitalized body. PlantX partnered with Venus earlier this year to help consumers embark on a plant-based journey, which can sometimes feel overwhelming. The tennis icon would also be a PlantX ambassador. In this role, she will advocate for the benefits of living a plant-based lifestyle as well as enhance awareness of PlantX’s product line through promotional posts. In addition to such collaborations and the resultant informative resources posted on YouTube, PlantX also updates its website with new blogs and articles about living a simple plant-based life. “Whether you follow a plant-based lifestyle or you’re a flexitarian, you can count on our news to guide you on this journey,” reads the website (https://ibn.fm/5SH1y). The posts include listicles, such as the Top 5 Best Natural Sweeteners, Top 5 Healthy Plant-Based Fats, and Top 5 Protein Sources to Build Lean Muscle;and explanatory articles such as How a Plant-Based Diet is Better for the Immune System, A Guide on How to Love Tofu, Plant Variegation 101, and Key vitamins and minerals for plant-based dieters. They also feature how-to’s, including How to care for Alocasia Polly and How to make a plant-based pesto,and more. Through its commitment to education, PlantX is making the plant-based lifestyle more accessible to all. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• In September 2020, SRAX acquired LD Micro, a leader in in small- and micro-cap conferences.
• After almost two years of virtual-only conferences because of COVID-19 restrictions, this year’s main event is both in-person and virtual
• LD Micro is utilizing technology of a multitude of presenting public companies to ensure the safety and comfort of all event attendees

In the small cap space, the premier conference every year is the LD Micro main event, a gathering of up-and-coming companies and the most powerful people in the small cap world. Owing to COVID-19, investors have been deprived of the in-person convention for almost two years, with pandemic rules in California restricting the conference to a virtual format during the outbreak. That is over, though, as the live event is back, taking place in person on October 12-14th at the Luxe Sunset Bel Air, marking it the first in-person event since LD Micro was acquired by SRAX (NASDAQ: SRAX) in September 2020. Since 2008, over 1,600 companies have presented to LD Micro’s large community of analysts and investors. LD Micro was founded by Chris Lahiji in 2006 for the sole purpose of being an independent resource in the microcap space. Started as a newsletter focused on companies with tiny market capitalizations, LD Micro grew into a well-respected data and event company providing exposure to companies that went on to great success, such as OptimizeRx Corp. (NASDAQ: OPRX) (https://ibn.fm/r9Yqx), which replaced Lydall Inc. (NYSE: LDL) in the S&P SmallCap 600 on Monday, October 4. In 2017, OptimizeRx, a regular at the LD main event previously, traded as low as $1.89 per share before it exploded upward, trading near $90 per share, currently with a market cap over $1.5 billion. The acquisition by LD Micro last year for approximately $7.61 million in cash and stock (total consideration accounts for cash received and adjustments per regulatory filings) was a natural bolt-on for SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its Sequire platform. Sequire is an intelligence and communications platform that uses cutting-edge technology to allow companies to follow their shareholders’ behaviors and trends, in turn using this information to engage current and potential investors across multiple marketing channels. With the acquisition, LD Micro and SRAX can cross-pollinate services to millions of investors and companies. SRAX founder and CEO Christopher Miglino said the acquisition would be immediately accretive and he apparently was correct, as evidenced by SRAX reporting a 557% year-over-year jump in Q2 revenue to $7.7 million. The growth undergirded SRAX announcing a $10 million stock buy-back program and special dividend for shareholders. This year’s main event will bring together both physical and virtual elements to form a truly unique experience. The event is expected to feature over 150 companies, each presenting for 25 minutes. Whether presented online or live, all presentations will be available for online viewing. LD Micro is taking special precautions to ensure the safety and comfort of all attending the in-person convention. LD Micro is working with a group of public companies in this capacity, with Todos Medical (OTCQB: TOMDF), TOMI(TM) Environmental Solutions (NASDAQ: TOMZ), Remark Holdings (NASDAQ: MARK), Energy Focus, Lakeland Industries (NASDAQ: LAKE), good natured Products (TSX.V: GDNP), Biomerica (NASDAQ: BMRA), Pure Bioscience (OTCQB: PURE), Nightfood Holdings (OTCQB: NGTF), and GreenPower Motor Company (NASDAQ: GP) (TSX.V: GPV) providing COVID-19 safety products or services during the event. “If the NBA can pack an indoor stadium with screaming, mask-less fans, we can have an outdoor get-together. The energy is going to be unmatched because people want to see their friends again, the same goes for me as well,” said Lahiji. Lahiji joined the SRAX board upon the completion of the acquisition and continues to lead LD Micro as a subsidiary of SRAX. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX